MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at…
MaaT PharmaDecember 8, 2025
MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update Positive results…
MaaT PharmaSeptember 17, 2025
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease…
MaaT PharmaJuly 2, 2025
June 19, 2025: MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 Marketing Authorization…
MaaT PharmaJune 19, 2025
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA…
MaaT PharmaJune 13, 2025
